Efekti inhibitora kotransportera natrijum-glukoze 2 na nealkoholnu masnu bolest jetre kod pacijenata sa dijabetesom tipa 2: meta-analiza randomiziranih kontroliranih studija.
Journal of diabetes investigation
Sažetak istraživanja
Ciljevi/uvod Nealkoholna masna bolest jetre (NAFLD) je sve češća kod pacijenata sa dijabetes melitusom tipa 2. Trenutno su neke studije otkrile da inhibitori natrijum-glukoznog kotransportera 2 (SGLT2), novi hipoglikemijski lijek, mogu poboljšati nealkoholnu masnu jetru pored svog hipoglikemijskog učinka. Stoga smo poduzeli meta-analizu randomiziranih kontroliranih studija kako bismo procijenili efikasnost inhibitora SGLT2 u liječenju NAFLD-a. Materijali i metode PubMed, Embase i Cochrane Biblioteka pretražene su za randomizirana kontrolirana ispitivanja inhibitora SGLT2 kod pacijenata s NAFLD i dijabetesom mellitusom tipa 2 do 1. listopada 2019. Razlike su izražene kao srednja razlika težine (WMD) sa 95% intervalom pouzdanosti (CI) za kontinuirani izlazni interval. I 2 statistika je primijenjena za procjenu heterogenosti studija.
Rezultati Ukupno šest studija koje uključuju 309 pacijenata odabrano je u našu meta-analizu. SGLT2 inhibitori mogu smanjiti alanin aminotransferazu (WMD -11,05 IU/L, 95% CI -19,85, -2,25, P = 0,01) i magnetnu rezonancu protonsku gustinu masne frakcije (WMD -2,07%, 95% CI -3,86, -0). Međutim, inhibitori SGLT2 nisu smanjili aspartat aminotransferazu (WMD -1,11 IU/L, 95% CI -2,39, 0,17, P = 0,09). Osim toga, smanjeni su i sekundarni ishodi, kao što su tjelesna težina i područje visceralne masti (WMD -1,62 kg, 95% CI -2,02, -1,23, P 2 , 95% CI -27,18, -12,79, P
Zaključci SGLT2 inhibitori mogu značajno smanjiti gubitak težine alanin i liverpanitrans masti pozitivan učinak na masnu jetru kod pacijenata sa dijabetesom mellitusom tipa 2. Ograničenje je u tome što je veličina uzorka bila mala, stoga su potrebna veća randomizirana kontrolirana ispitivanja za procjenu ovih rezultata.
Prikaži originalni naslov i sažetak na engleskom
Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Aims/introduction Non-alcoholic fatty liver disease (NAFLD) is increasingly common in patients with type 2 diabetes mellitus. Currently, some studies have found that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new hypoglycemic drug, can improve non-alcoholic fatty liver in addition to its hypoglycemic effect. Thus, we undertook a meta-analysis of randomized controlled trials to evaluate the efficacy of SGLT2 inhibitors on the treatment of NAFLD. Materials and methods PubMed, Embase and the Cochrane Library were searched for randomized controlled trials of SGLT2 inhibitors in patients with NAFLD and type 2 diabetes mellitus up to 1 October 2019. Differences were expressed as weight mean difference (WMD) with 95% confidence interval (CI) for continuous outcomes. The I 2 statistic was applied to evaluate the heterogeneity of studies.
Results A total of six trials including 309 patients were selected into our meta-analysis. SGLT2 inhibitors could reduce alanine aminotransferase (WMD -11.05 IU/L, 95% CI -19.85, -2.25, P = 0.01) and magnetic resonance imaging proton density fat fraction (WMD -2.07%, 95% CI -3.86, -0.28, P = 0.02). However, SGLT2 inhibitors did not reduce aspartate aminotransferase (WMD -1.11 IU/L, 95% CI -2.39, 0.17, P = 0.09). In addition, secondary outcomes, such as bodyweight and visceral fat area, were also reduced (WMD -1.62 kg, 95% CI -2.02, -1.23, P 2 , 95% CI -27.18, -12.79, P
Conclusions SGLT2 inhibitors can significantly decrease alanine aminotransferase and liver fat, accompanied with weight loss, which might have a positive effect on fatty liver in patients with type 2 diabetes mellitus. The limitation is that the sample size of the studies was small. Therefore, more large randomized controlled trials specified on NAFLD are required to evaluate these results.
Izvorni podaci
- DOI
- 10.1111/jdi.13237
- PMID
- 32083798
- PMCID
- PMC7477503
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom